Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 6;10(9):181-194.
doi: 10.1177/1759720X18793317. eCollection 2018 Sep.

The role of golimumab in inflammatory arthritis. A review of the evidence

Zunera Tahir  1 , Arthur Kavanaugh  2
Affiliations
Review

The role of golimumab in inflammatory arthritis. A review of the evidence

Zunera Tahir et al. Ther Adv Musculoskelet Dis. .

Abstract

Background: Golimumab (GOL) is a tumor necrosis factor inhibitor that is used for various types of inflammatory arthritis such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This article is a systematic review of the evidence for the efficacy and safety of golimumab in inflammatory arthritides, specifically RA, PsA and AS.

Methods: We conducted a search of randomized controlled trails in MEDLINE [PubMed], CENTRAL, Embase, and Current Controlled Trials databases (ClinicalTrials.gov) through 2017 for studies that evaluated golimumab in inflammatory arthritides. We focused on pivotal, phase III trials for this review of the safety and efficacy of the drug. However, as some important information is not available in detail in publications from the phase III studies, additional individual studies pertaining to antidrug antibodies were also included.

Results: A total of 12, randomized, double-blind, placebo-controlled studies were included in this review of literature. Two trials focused on the GOL response in the PsA population, four trials focused on the GOL response in the AS population, and five trials focused on the GOL response in the RA population. Additional studies that evaluated autodrug antibodies produced in patients using GOL were also included.

Conclusion: Golimumab was found to be clinically effective and also have a good safety profile in the treatment of RA, PsA, and AS based on data available from large studies.

Keywords: Golimumab; ankylosing spondylitis; inflammatory arthritides; psoriatic arthritis; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Dr Arthur Kavanaugh has conducted clinical research studies sponsored by Janssen.

References

    1. Deodhar A, Braun J, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis 2015; 74: 757–761. - PMC - PubMed
    1. Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-α inhibitors. Expert Opin Drug Saf 2012; 11: 1–5. - PubMed
    1. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387–1394. - PMC - PubMed
    1. Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis 2014; 73: 1689–1694. - PMC - PubMed
    1. Kavanaugh A, Husni ME, Harrison DD, et al. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis. Arthritis Rheumatol 2017; 69: 2151–2161. - PMC - PubMed

LinkOut - more resources